Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31319868 | 1.00 | NOS3 (0.34) | NOS3NOS1NOS2ALDH1A1LMNA | |
| SCHEMBL3952885 | 0.84 | ALDH1A1 (0.38) | ALDH1A1LMNATRPA1GAAHSD17B3 | |
| SCHEMBL27980877 | 0.83 | ALDH1A1 (0.34) | ALDH1A1LMNAGAAHSD17B3MAPT | |
| SCHEMBL27334616 | 0.80 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B3MAPTHSD17B10 | |
| SCHEMBL4111485 | 0.80 | NOS2 (0.44) | NOS3NOS1NOS2ALDH1A1LMNA | |
| SCHEMBL31434931 | 0.77 | PARP1 (0.36) | ALDH1A1MAPTHSD17B10PARP1SMN1; SMN2 | |
| SCHEMBL23093721 | 0.75 | MAPK1 (0.39) | ALDH1A1LMNAGAAHSD17B3MAPT | |
| SCHEMBL24290549 | 0.73 | MAPT (0.32) | MAPTHSD17B10SMN1; SMN2ALOX15 | |
| SCHEMBL8317265 | 0.72 | ALOX15 (0.36) | ALDH1A1LMNAGAAHSD17B3MAPT | |
| SCHEMBL28223560 | 0.70 | MAPT (0.36) | ALDH1A1LMNAGAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191379-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | 재단법인 대구경북첨단의료산업진흥재단 | 2023-10-05 | — | — | WO | claimed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250214947-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | CUREVERSE INCORPORATED (KR) | 2025-07-03 | — | — | US | disclosed |
| EP-4501917-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023191379-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | 재단법인 대구경북첨단의료산업진흥재단 | 2023-10-05 | — | — | WO | disclosed |
| EP-1660460-A1 | QUINOXALINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021512-A1 | QUINOXALINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | NOS3 2951/4885NOS1 3860/4885NOS2 4513/4885 |
| US-20250214947-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | HDAC8, HDAC1, HDAC5 | NOS3 2148/4885NOS1 2934/4885NOS2 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.